年間契約型資訊服務

中國的醫藥品和醫療保健產品的市場

China Pharmaceuticals & Healthcare

出版商 Fitch Solutions, Inc. 商品編碼 940152
出版日期 年間契約型資訊服務 內容資訊 英文 97 Pages
價格
中國的醫藥品和醫療保健產品的市場 China Pharmaceuticals & Healthcare
出版日期: 年間契約型資訊服務內容資訊: 英文 97 Pages
簡介

中國,目的將醫藥品的價格降低推動法規的變更等,伴隨新型冠狀病毒感染疾病(COVID-19)的大流行的研究開發投資也擴大,成為對醫藥品市場來說強大的順風。降低廣泛使用藥品價格的法規變化,連同加快批准過程的努力,預計將推動創新新藥的開發。

本服務,提供中國的醫藥品和醫療保健產品的市場調查,產業的展望,處方藥,取得專利的醫藥品,學名藥,OTC藥的市場預測,產業的風險,藥事法規,第13次五年計劃的要點,企業簡介等資訊。

目錄

  • 主要的見解
  • Covid-19的影響
  • SWOT分析
  • 產業預測
  • 醫藥品市場預測
  • 醫療保健產品市場預測
  • 處方藥市場預測
  • 取得專利的醫藥品市場預測
  • 學名藥市場預測
  • OTC藥市場預測
  • 醫藥品貿易的預測
  • 產業風險/利益指數
  • 亞太地區的創新的醫藥品的風險/利益指數
  • 創新的醫藥品的風險/利益指數
  • 藥事法規的發展
  • 藥事法規的檢討
  • 第13次5年計劃的要點
  • 市場概要
  • 競爭情形
  • 企業簡介
  • AstraZeneca
  • Bayer HealthCare
  • China Shijiazhuang Pharmaceutical Group (CSPC)
  • Eli Lilly (Lilly China)
  • GlaxoSmithKline
  • MSD
  • Merck KGaA
  • North China Pharmaceutical Corporation
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Shanghai Pharmaceuticals Holding Co
  • Sinopharm
  • 中國的人口統計預測
  • 詞彙表
  • 調查手法
目錄
Product Code: SSCN03_20201001

Key View: Growth in the Chinese pharmaceutical market will gradually slow beyond 2020, as we expect the government to tighten its already constrained expenditure on healthcare. Though an ageing population will present opportunities for innovative drugmakers targeting age-related diseases, the government will likely maintain a long-term focus on cost-containment measures. The Covid-19 pandemic poses a more immediate risk to our forecast, causing downward pressure on the economy which will have very direct implications for healthcare and pharmaceutical spending.

Table of Contents

  • Key View
  • China Pharmaceuticals & Healthcare Covid-19 Impact
  • SWOT
  • Industry Forecast
  • Pharmaceutical Market Forecast
  • Healthcare Market Forecast
  • Prescription Drug Market Forecast
  • Patented Drug Market Forecast
  • Generic Drug Market Forecast
  • OTC Medicine Market Forecast
  • Pharmaceutical Trade Forecast
  • Industry Risk/Reward Index
  • Asia Pacific Innovative Pharmaceuticals Risk/Reward Index
  • Innovative Pharmaceuticals Risk/Reward Index
  • Regulatory Development
  • Regulatory Review
  • 13th Five-Year Plan: Key Points
  • Market Overview

Competitive Landscape

  • Company Profile
  • AstraZeneca
  • Bayer HealthCare
  • China Shijiazhuang Pharmaceutical Group (CSPC)
  • Eli Lilly (Lilly China)
  • GlaxoSmithKline
  • MSD
  • Merck KGaA
  • North China Pharmaceutical Corporation
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Shanghai Pharmaceuticals Holding Co
  • Sinopharm
  • China Demographic Outlook
  • Pharmaceuticals & Healthcare Glossary
  • Pharmaceuticals & Healthcare Methodology